Speaking To AstraZeneca And Huma About Digital’s Value For Pharma
Executive Summary
AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.
You may also be interested in...
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
Minute Insight: Huma Buys AstraZeneca’s Amaze Digital Health Platform For Chronic Disease
The companies will continue to collaborate to expand the reach of AstraZeneca's Amaze platform for chronic disease while launching companion applications.
News We’re Watching – US FDA Updates, Digital Therapeutics Legislation, AI Endoscopies, Monkeypox EUA, And New AdvaMed Chair
The US Food and Drug Administration recently issued updates regarding improvements to its online submissions portal, enhancements to its electronic medical device reporting system, pediatric X-ray guidance, expanded indications for a popular breathing device, and mammogram guidelines; and more news we’re watching.